Cambridge Neuroscience Cerestat
Boehringer Ingelheim dissolves collaboration to develop Cerestat (aptiganel) for the treatment of traumatic brain injury and stroke with Cambridge Neuroscience following cancellation of Phase III clinical trials begun in 1996. Cambridge said it intends to pursue development of aptiganel through a new collaboration. Outstanding issues in the dissolution include the financial terms of Cambridge's use of data generated by the two companies, Cambridge's repayment of amounts due Boehringer, and the amount Boehringer will charge Cambridge for drug inventory
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth